National Institutes of Health: Fibrous Dysplasia, Polyostotic trials

The registry lists 10 Fibrous Dysplasia, Polyostotic studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 2 have results posted.

Phase 1 2Phase 2 5Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright SyndromeRecruitingNCT00001727
• Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous DysplasiaCompletedNCT05509595Phase 2Results posted
• PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright SyndromeCompletedNCT02743377Phase 1/2Results posted
• Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous DysplasiaCompletedNCT05419050Phase 2
• A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright SyndromeCompletedNCT00017927Phase 3
• Effects of Letrozole on Precocious Puberty Due to McCune Albright SyndromeCompletedNCT00006174Phase 1
• Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright SyndromeCompletedNCT00001973
• Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright SyndromeCompletedNCT00001851
• Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright SyndromeCompletedNCT00001728Phase 2
• Testolactone for the Treatment of Girls With LHRH Resistant Precocious PubertyCompletedNCT00001181Phase 2